While traditionally used as antidiabetic agents, SGLT2 inhibitors have demonstrated efficacy in slowing renal disease progression and reducing the risk of ESRD in both T2DM and HF patients, regardless of diabetes status. This evidence concerns the gene SLC5A2 and diabetes mellitus.